After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

The company's comparison of its ADCs to Enhertu seems farfetched.

Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.